Jason E. Farrar

High Impact

Professor

UAMS

Also affiliated: Children's Oncology Group (2016–2023); Synlab Czech (Czechia) (2021); Cincinnati Children's Hospital Medical Center (2025); Arkansas Children's Hospital (2014–2026); St. Jude Children's Research Hospital (1996); Johns Hopkins University (2005–2012); Chiba University (2008); University of Tennessee Health Science Center (1996); University of Arkansas Medical Center (2024); National Human Genome Research Institute (2015); Winthrop Rockefeller Foundation (2016–2021); Arkansas Children's Nutrition Center (2025); Johns Hopkins Hospital (2009); Sidney Kimmel Comprehensive Cancer Center (2007–2012)

Faculty Researcher

Peds Pediatrics, College of Medicine

25 h-index 149 pubs 3,161 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Jason E. Farrar studies pediatric acute myeloid leukemia (AML) and Diamond-Blackfan anemia. His research investigates the molecular and clinical characteristics of these conditions, including specific gene fusions like NUP98 and the role of long noncoding RNAs in predicting outcomes for pediatric AML. Farrar has also examined the mechanisms by which certain genetic alterations, such as ZMYND11-MBTD1, contribute to leukemogenesis through interactions with chromatin remodeling complexes.

His work includes contributions to international consensus statements on the diagnosis, treatment, and surveillance of Diamond-Blackfan anemia. Farrar is also involved in research on implementing pharmacogenomics testing in pediatric settings, as demonstrated by his experience at Arkansas Children’s Hospital. He has received funding from the NIH/National Center for Advancing Translational Sciences as a Co-PI for the CTSA K12 Program at the University of Arkansas for Medical Sciences, totaling $756,000.

Farrar holds the designation of a high-impact researcher, evidenced by his h-index of 25 and over 3,000 citations across 149 publications. His key collaborators include Samrat Roy Choudhury, Lauren Appell, Stephanie D. Byrum, and LE Appell, all from the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications.

Metrics

h-index: 25
Publications: 149
Citations: 3,161

Selected Publications

Feasibility of Non-Sedated Multispectral Neuroimaging in Newly Diagnosed Children with Leukemia (2026)

medRxiv DOI OpenAlex
Abstract 3496: Epigenetic repurposing by CBFA2T3-GLIS2 reveals a druggable DNA methylation axis in high-risk pediatric AML vulnerability in pediatric AML (2026)

Cancer Research DOI OpenAlex
Central nervous system-symptomatic hyperammonemia following recombinant crisantaspase Pseudomonas fluorescens (2026)

The American Journal of the Medical Sciences DOI OpenAlex
A supervised STreNgth & Outpatient Exercise Regimen in pediatric patients with Acute Lymphoblastic Leukemia (STRONGER ALL) (2026)

The American Journal of the Medical Sciences DOI OpenAlex
Abstract PR006: CBFA2T3–GLIS2 fusion reprograms enhancer-linked DNA methylation to enforce apoptotic resistance and defines an epigenetic vulnerability in pediatric AML (2026)

Cancer Research DOI OpenAlex
Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia (2025)

Genes & Diseases 1 citation DOI OpenAlex
Germline Variant Burden Warrants Universal Genetic Testing in Pediatric Myeloid Leukemia (2025)

medRxiv DOI OpenAlex
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial (2025)

Blood Advances 12 citations DOI OpenAlex
130 A supervised strength and outpatient exercise regimen in pediatric patients with acute lymphoblastic leukemia (STRONGER ALL) (2025)

Journal of Clinical and Translational Science DOI OpenAlex
Lymphoid malignancies in patients with Shwachman-Diamond syndrome (2025)

Blood 3 citations DOI OpenAlex
Lymphoid Malignancies in Shwachman-Diamond Syndrome (2024)

Blood DOI OpenAlex
Evaluation of recurrent and recalcitrant warts in a deaf adolescent male reveals GATA2 deficiency (2024)

Journal of Allergy and Clinical Immunology Global 1 citation DOI OpenAlex
Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement (2024)

The Lancet Haematology 61 citations DOI OpenAlex
Abstract P16: CBFA2T3-GLIS2 fusion leads to a distinct DNA methylation enhancer landscape in pediatric acute myeloid leukemia (2024)

Blood Cancer Discovery 1 citation DOI OpenAlex
Enhancer‐activated <scp>RET</scp> confers protection against oxidative stress to <scp>KMT2A</scp>‐rearranged acute myeloid leukemia (2024)

Cancer Science 9 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $756,000 total

NIH Co-PI Jul 2024 - Jun 2029

CTSA K12 Program at the University of Arkansas for Medical Sciences

National Center for Advancing Translational Sciences $756,000 K12

Grants & Funding

As listed on this researcher's institutional profile. Federal awards with verified records are shown above.

GR034151 Farrar ACHRI Mechanisms of Erythroid Remission in Diamond Blackfan Anemia (DBA) UAMS ACHRI Flow Through Principal Investigator
Integrative Genomics in Pediatric AML Arkansas Children's Research Institute Principal Investigator
Role of HELB in the Replication Stress Response Dr. Tacketts COBRA through ACRI NIH/Nat. Inst. of General Medical Sciences via Arkansas Children's Research Institute Principal Investigator
St. Baldrick's Subaward St. Baldrick's Foundation via Fred Hutchinson Cancer Research Center Principal Investigator
GR039178-Farrar-ACRI Proteogenomics Core UAMS ACHRI Flow Through Principal Investigator
Tackett COBRE-SUBAward J Farrar Project 1 - Continuation - Continuation NIH/Nat. Inst. of General Medical Sciences via Arkansas Children's Hospital Principal Investigator
Epigenomic Characterization of Pediatric AML UAMS ACHRI Flow Through Principal Investigator
Mechanisms of Erythroid Remission in Diamond Blackfan Anemia (DBA) NIH Principal Investigator